Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio cut its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 5.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 54,729 shares of the life sciences company's stock after selling 3,133 shares during the quarter. Public Employees Retirement System of Ohio's holdings in Illumina were worth $7,313,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Bank of Stockton boosted its stake in Illumina by 3.8% during the fourth quarter. Bank of Stockton now owns 2,162 shares of the life sciences company's stock worth $289,000 after buying an additional 80 shares during the period. Stephens Inc. AR boosted its stake in Illumina by 1.4% during the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company's stock worth $885,000 after buying an additional 90 shares during the period. Spire Wealth Management boosted its stake in Illumina by 26.0% during the fourth quarter. Spire Wealth Management now owns 470 shares of the life sciences company's stock worth $63,000 after buying an additional 97 shares during the period. IFP Advisors Inc boosted its stake in Illumina by 19.1% during the fourth quarter. IFP Advisors Inc now owns 617 shares of the life sciences company's stock worth $82,000 after buying an additional 99 shares during the period. Finally, Freedom Investment Management Inc. boosted its stake in Illumina by 3.7% during the fourth quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock worth $382,000 after buying an additional 101 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Ankur Dhingra acquired 6,100 shares of the business's stock in a transaction dated Monday, May 12th. The shares were purchased at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the acquisition, the chief financial officer now directly owns 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.60% of the stock is currently owned by corporate insiders.

Illumina Stock Down 3.5%

Illumina stock traded down $2.91 during trading hours on Friday, reaching $81.37. The stock had a trading volume of 3,660,293 shares, compared to its average volume of 2,333,388. The company has a market cap of $12.88 billion, a price-to-earnings ratio of -10.60, a PEG ratio of 1.60 and a beta of 1.35. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The business's 50 day moving average price is $77.73 and its 200-day moving average price is $106.64. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The firm's revenue was down 1.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.98 earnings per share. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ILMN shares. Hsbc Global Res lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. JPMorgan Chase & Co. lowered their target price on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Stephens reissued an "overweight" rating and set a $105.00 target price on shares of Illumina in a research note on Tuesday, May 20th. Citigroup lowered their target price on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. Finally, Morgan Stanley lowered their target price on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a research note on Monday, May 12th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $128.15.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.